Background. We used biochemical and immunohistochemical techniques to investigate the expression and distribution of immunoreactive basic and acidic fibroblast growth factors (bFGF and aFGF, respectively) in the hearts of rat embryos (11-20 days of gestation) and of postnatal rats (1-35 days after birth). Our purpose was to assess the relation between the cellular distribution of these growth factors and histogenetic and morphogenetic events in the developing heart.
Immunohistochemical Localization of Basic
and Acidic Fibroblast Growth Factors in the Developing Rat Heart Paolo Spirito, MD; Ya-Min Fu, MD; Zu-Xi Yu, MD; Stephen E. Epstein, MD; and Ward Casscells, MD Background. We used biochemical and immunohistochemical techniques to investigate the expression and distribution of immunoreactive basic and acidic fibroblast growth factors (bFGF and aFGF, respectively) in the hearts of rat embryos (11-20 days of gestation) and of postnatal rats (1-35 days after birth). Our purpose was to assess the relation between the cellular distribution of these growth factors and histogenetic and morphogenetic events in the developing heart.
Methods and Results. Western-blot analysis of heparin-bound material from neonatal heart extracts identified a single band with a molecular weight of approximately 18 kD for both bFGF and aFGF. Five antibodies for bFGF and three for aFGF showed superimposable distribution of immunoreactive bFGF and aFGF in the heart at each stage examined. At the cellular level, these peptides were localized in the cytoplasm and extracellular matrix. In the myocytes, immunostaining was positive throughout the embryonic and neonatal periods. In the majority of the mesenchymal cells of the cushions and endothelial cells of endocardium and vessels, staining was also positive. In the smooth muscle cells of the aorta, other large arteries, and coronary arteries, immunostaining was intensely positive at early stages of development but became faint or negative with increasing cell differentiation.
Conclusions. The wide distribution of immunoreactive bFGF and aFGF that we identified in the developing rat heart suggests that these growth factors play an important role in heart cytodifferentiation and morphogenesis. Their superimposable distribution may reflect functional interaction. The progressive changes in their distribution suggest a changing role for these peptides during organogenesis. (Circulation 1991;84:322-332) T hree growth factors -basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), and transforming growth factor-,X3 (TGF-,31) -have been identified in the hearts of lower vertebrates and mammals, including humans.1-9 In vitro, these peptides have been shown to have regulatory effects on many cellular functions, such as cell proliferation and differentiation, matrix formation, and cell movement. [10] [11] [12] Their biological functions in vivo remain largely unknown.
Recently, there has been increasing interest in the possible role of these peptides in pathological conditions associated with tissue growth in the heart and heart vessels, such as myocardial hypertrophy and smooth muscle cell proliferation in coronary athero-From the Cardiology Branch, National Heart, Lung, and Blood sclerosis and coronary restenosis after angioplasty. However, basic questions regarding the physiological roles of these growth factors must be answered before the issue of their roles in pathological conditions can be addressed.
Previous observations suggest that bFGF and aFGF may have important effects on cellular differentiation and tissue growth in embryos. In vitro, bFGF and aFGF are mitogenic and induce differentiation in numerous cell types.'0-15 In vivo, bFGF has been shown to stimulate the growth of transplanted rat embryos.'6 With immunohistochemical techniques, bFGF has been identified in the heart and striated muscle of chick embryos from early to late stages of development' and in tissues of mesodermal and neuroectodermal origin in rat embryos at 18 days of gestation.6
In the present study, we used biochemical and immunohistochemical techniques to investigate the expression and the cellular and tissue distribution of bFGF and aFGF in the heart and vessels of rat embryos at different stages of development (11-20 days of gestation) and of postnatal rats (1 day to 5 weeks after birth). The purpose of our study was to investigate the relation between the distribution of these two growth factors and critical histogenetic and morphogenetic events in the heart. In addition, we compared the distribution of bFGF and aFGF in the heart with that of TGF-31, a growth factor that may also play a role in heart development. 8, 9 Methods The cellular and tissue distribution of bFGF, aFGF, and TGF-,81 were investigated in the hearts of Sprague-Dawley rat embryos (approximately 60 embryos) and postnatal rats (n=32) at different stages of development. Embryos were studied from day 11 to day 20 of gestation (crown-to-rump lengths of embryos ranged from 2 to 23 mm). We chose day 11 as the earliest stage for study because main organs first become recognizable on this day. Postnatal rats were studied 1 and 3 days and 1, 2, 4, and 5 weeks after birth.
Antibodies
For identification of bFGF, three polyclonal antibodies and two monoclonal antibodies were used. All of the three polyclonal antibodies were raised in rabbit: One (773) was raised against the first 24 amino acids of bovine bFGF (PAL ... RLY residues); a second (967) was raised against human recombinant bFGF (whole molecule); and a third (C-terminal) was raised against the amino acid sequence of 135 to 145 of bovine bFGF (AIL . . . AKS residues). The antibodies 773 and 967 are IgG purified and were kindly provided by Dr. Andrew Baird (Whittier Institute, La Jolla, Calif.), and the C-terminal antibody was a gift from Dr. Joachim Sasse (Shriner's Hospital for Crippled Children, Tampa, Fla.). The cross-reactivity to aFGF of antibody 773 is 2%, and those of antibody 967 and the C-terminal antibody are less than 1% in Western blots. The two monoclonal antibodies were prepared from BALB/c mice using the hybridoma technique; one (78) recognizes the epitope located at the first nine residues of the human recombinant bFGF, and the other (98) recognizes the site between the amino acid residues 14 and 40. These two monoclonal antibodies were the kind gift of the Pharmaceutical Group, Takeda Chemical Industries, Ltd., Japan.'7 In our laboratory, each of these monoclonal antibodies showed high specificity without detectable binding to aFGF in Western blots. The stock concentrations for these antibodies were as follows: 2 mg/ml for antibodies 773 and 967, 2.4 mg/ml for antibody 78, and 5.8 mg/ml for antibody 98.
For identification of aFGF, two polyclonal antibodies and a monoclonal antibody were used. The two polyclonal antibodies (63 and 119) were raised in rabbit against the amino acid sequence from 65 to 97 of human/bovine aFGF (SIG ... NEE residues) and were kindly provided by Dr. Joachim Sasse. The cross-reactivity of these two antibodies with bFGF is 1% in Western blots. The monoclonal antibody was prepared from BALB/c mice against bovine aFGF using the hybridoma techniques; it was purchased from Upstate Biotechnology Inc., Lake Placid, N.Y. This monoclonal antibody recognizes the tyrosine 111-to-lysine 126 region of aFGF and has very little cross-reactivity with bFGF (less than 1% in Western blots in our laboratory). The stock concentrations for these antibodies were as follows: 28 mg/ml for antibody 63, 34 mg/ml for antibody 119, and 1 mg/ml for the monoclonal antibody.
For identification of TGF-031, two polyclonal antibodies were used, which were kindly provided by Dr. Michael Sporn and Dr. Kathleen Flanders (National Cancer Institute, National Institutes of Health, Bethesda, Md.). Each of these antibodies was raised in rabbit; one antibody (LC) was raised against the amino acid sequence of 1 to 30 of mature TGF-81,8 and the other antibody (anti-pre) was raised against the amino acid sequence of 266 to 278 of the precursor of TGF-131.'8 The stock concentrations for the LC antibody and anti-pre were 1.2 and 2.5 mg/ml, respectively.
Immunohistochemistry
The distribution of bFGF, aFGF, and TGF-f31 in the developing rat heart were investigated by immunohistochemical staining of sagittal and cross sections of rat embryos obtained at heart level and of sagittal and cross sections of hearts isolated from postnatal rats. Tissues were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer, (pH 7.4) overnight at 4°C. A Bouin solution and an acetic acid solution in ethanol were also initially used for tissue fixation, but they yielded less satisfactory results. After dehydration through a graded series of ethanol solutions, tissues were embedded in paraffin blocks. Sections from each block (6 gm in thickness) were stained with hematoxylin and eosin, Masson, and Yajima (periodic acid-methenamine silver staining) methods for routine morphological evaluation. For identification of growth factors, sections were immunostained using the following steps: 1) blocking of endogenous peroxidase with 3% hydrogen peroxide in methanol (30 minutes); 2) treatment with 2 mg/ml hyaluronidase type IV-S (H-3884, Sigma Chemical Co., St. Louis, Mo.) in 0.1 M acetate buffer (pH 5.1) (15 minutes); 3) blocking of nonspecific protein binding with 5% goat serum in 50 mM Tris buffer (pH 7.4) (1 hour); 4) incubation with primary antibodies, at suitable dilution at 4°C overnight (for bFGF, dilutions were 1:500 for each antibody used; for aFGF, dilutions were 1:1,000 for polyclonal antibody 63, 1:500 for polyclonal antibody 119, and 1:400 for monoclonal antibody; for TGF-,81, dilution was 1:500); 5) incubation with peroxidase-labeled affinity-purified goat anti-rabbit IgG for the polyclonal antibodies (Vector Laboratories, Inc., Burlingame, Calif.) and incubation with peroxidase-labeled affinity-purified horse anti-mouse IgG for the monoclonal antibodies (Vector) (1 hour); 6) treatment with 0.25 mg/ml diaminobenzidine (Sigma Chemical) in 0.05 M Tris HCl-buffered saline containing 0.01% hydrogen peroxide (10 minutes); and 7) counterstaining with 1% methyl green solution (2 minutes). The buffer solution used for rinsing after each step consisted of 0.01 M Tris-HCI-buffered saline and 0.25% Brij-35 (Sigma Chemical) (pH 7.4). Except when otherwise specified, all steps were performed at room temperature.
Immunohistochemical Controls for aFGF, bFGF, and TGF-f31
No immunostaining was seen in sections after the following immunohistochemical control procedures: 1) omission of the primary antibody and incubation with normal rabbit serum at the same (or more concentrated) dilutions used for the primary antibody, 2) omission of the primary antibody and incubation with 2% normal goat serum, and 3) omission of the primary antibody and incubation with nonimmune mouse IgG at the same (or more concentrated) dilutions used for the primary antibody.
In addition, specificity of immunostaining was confirmed for each antibody by incubation with primary antibody preabsorbed by its corresponding growth factor, as described below. Two different procedures were used for absorption of each antibody for bFGF and aFGF. First, after blocking of nonspecific protein binding with 5% goat serum in 50 mM Tris buffer (pH 7.4) (1 hour), sections were incubated overnight with preabsorbed antibody at 4°C. Preabsorbed antibody was obtained as follows: antibody at suitable dilutions (total volume, 0.3 ml) was incubated overnight with heparin-Sepharose beads coupled with 100-200 g aFGF or bFGF at 4°C. Supernatant was used as preabsorbed antibody. Second, after blocking of nonspecific protein binding, like in the first procedure, specific blocking of fibroblast growth factor binding sites was obtained as follows. Sections were incubated with 50-100 ,ug/ml of human recombinant aFGF or bFGF, as appropriate, in 0.2 ml of 2% goat serum, at room temperature for 1 hour and subsequently at 4°C for 2 hours. Then, the peptide was removed, and sections were incubated with primary antibody. For absorption of anti-pre antibody for TGF-3,l, the procedure used was that described by Flanders et al. 18 For each antibody and with each procedure, no immunostaining was seen in sections. Extraction of aFGF and bFGF From Neonatal Rat Hearts bFGF and aFGF were extracted from hearts obtained from neonatal rats at days 1, 3, 7, and 14 after birth. At each stage, total weights of hearts ranged from 1 to 1.5 g. After being frozen in liquid nitrogen, hearts were briefly homogenized (30 seconds) using a polytron in a solution eightfold to 10-fold the volume of the tissue. The solution contained 0.5 M NaCl, 20 mM Tris, 3 mM EDTA, and 0.2 mM PMSF, at pH 6.5. During homogenization, the temperature was kept below 10°C with ice. The homogenized tissue underwent three freeze/thaw cycles and then was centrifuged at 48,00Og for 120 minutes. The clear supernatant (1-2 ml), in 0.5 M NaCl, was batchabsorbed overnight with 0.4 ml heparin-Sepharose beads, while being gently rocked. After being transferred to a column, the beads were washed with 0.6 M NaCl in 10 mM Tris and eluted with a step gradient of 1.1, 1.5, and 3.0 M NaCl in 10 mM Tris. Aliquots were obtained for Western-blot analysis and mitogenicity assays for BALB/c/3T3 cells.'9
Western-Blot Analysis for bFGF and aFGF Column fractions were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis in 10-20% gradient gel and then transferred to nitrocellulose membrane (0.05 ,im; Schleicher & Schuell, Inc., Keene, N.H.) by electrophoretic transfer (PolyBlot Transfer System, model SBD-1000, American Bionetics, Emeryville, Calif.). After transfer and blocking of the nonspecific protein binding sites with 1% dry milk in triethanolamine-buffered saline, the nitrocellulose membrane was incubated with different antibodies at suitable dilutions (1: 1,000 for monoclonal antibody 78 and polyclonal antibody 773 for bFGF; 1: 500 for monoclonal antibody and 1: 1,000 for polyclonal antibody 119 for aFGF) in wash buffer (10 mM Tris HCI, pH 8.0, 0.15 M NaCl, and 0.05% Tween-20) overnight at 4°C. Antigen-antibody complexes were visualized by incubating the membrane with suitable secondary antibodies and developing it by ProtoBlot Western Blot AP System (Promega, Madison, Wis.).
Results

Identification of bFGF and aFGF in Neonatal Rat Hearts
Western-blot analysis for bFGF and aFGF was performed on heparin-bound material from neonatal rat heart extracts obtained on days 1 and 14 after birth. At each stage and with each of the antibodies used in the present study, a single band with a molecular weight of approximately 18 kD was detected for both bFGF and aFGF (Figure 1 ). Mitogenic activity for 3T3 fibroblasts was present in fractions obtained from extracts of 1-, 3-, 7-, and 14-day neonatal hearts. These fractions were eluted from heparin-Sepharose columns in two broad peaks at 1.1 and 1.5 M NaCl (data not shown).
Immunohistochemical Localization of bFGF and aFGF in Embryonic and Postnatal Rat Hearts
Each of the different antibodies used for bFGF and aFGF showed a superimposable pattern of staining for the corresponding peptide in the heart of rat embryos and postnatal rats. Omission of the primary antibodies and absorption of each antibody confirmed the specificity of the immunostaining (Figure 2) . The cellular and tissue distribution of immunoreactive bFGF and aFGF were superimposable at each stage examined; the two peptides were localized in the cytoplasm as well as in the extracellular matrix. We found similar changes in the distribution of bFGF and aFGF during development (Figures 3 and 4 ). In the developing myocytes, immunoreactivity for bFGF and aFGF was positive and intense from the earliest stages examined (days 11 and 12 of gestation), and it remained positive throughout embryonic development and the postnatal period (Figures 3A-3G and 4F).
In most endothelial cells of the endocardium and vessels, immunoreactivity for bFGF and aFGF was positive from the earliest stages of differentiation (days 11 and 12 of gestation), whereas in a minority of endothelial cells, it was faint or negative ( Figures  3A, 3B, and 3E ). In the capillaries, this nonuniform pattern of staining of the endothelial cells was maintained throughout the embryonic and postnatal stages examined ( Figure 3F ). In the media of the aorta and other large arteries (e.g., the aortic arches), at early stages of development (days 13 and 14), immunoreactivity for bFGF and aFGF was as intense as in the surrounding mesenchyma ( Figure 4B ). At this stage, the media of these arteries is formed by only one layer of smooth muscle cells. At later stages of embryonic development (days 15 and 16), immunostaining for bFGF and aFGF in the smooth muscle cells of the media of the aorta and other large arteries (now a multilayer structure) became faint and clearly less intense than that of the surrounding mesenchyma ( Figures 4C and  4D) , and it remained unchanged throughout the postnatal period examined (1 day to 5 weeks). In the smooth muscle cells of the monolayer media of the intramural coronary arteries, immunoreactivity for bFGF and aFGF was positive during the first days after birth, and it was as intense as that of the surrounding myocytes ( Figure 4E ). After the first week, however, staining for bFGF and aFGF in the now multilayer media of some intramural coronary arteries became faint or negative and clearly less intense than that of the surroundings myocytes. At the last stages examined (4-5 weeks), the smooth muscle cells of the media of most intramural coronary arteries showed faint or negative staining ( Figure 4F ).
In the mesenchymal cells that form the cushions at the base of the heart, immunoreactivity for bFGF and aFGF showed progressive changes during heart development. When the cushions first became recognizable (days 13 and 14) ( Figure 3C ), they showed positive and uniform staining. At later stages (days 15-17), inmmunostaining for bFGF and aFGF became nonuniform, with some areas of the cushions showing intense staining and others showing only faint staining ( Figure 3D) . At days 19 and 20, when the cardiac valves are almost completely developed, immunostaining for bFGF and aFGF was positive in the endothelium and connective tissue of the valves. Staining of the cardiac valves remained positive throughout the postnatal stages examined ( Figure 3G ).
Comparison of Immunohistochemical Localization of
TGF-f1 With That of bFGF and aFGF
In the developing rat heart, we also compared the cellular and tissue distribution of immunoreactive TGF-f81 with those of bFGF and aFGF. In both the embryonic and the postnatal heart and with each of the two antibodies used in the present study, the distribution of immunoreactive TGF-j31 was substantially similar to the distributions of bFGF and aFGF ( Figure 5 ). Like for the other two growth factors, immunostaining for TGF-,f1 was positive in the cardiac myocytes throughout the developmental stages examined. From the earliest stages of differentiation, immunostaining for TGF-P1 was also positive in the endothelial cells of the endocardium and vessels and in the mesenchymal cells that form the cardiac cushions ( Figure SB ). Furthermore. like bFGF and aFGF, immunoreactivity for TGF-f31 in the smooth muscle cells of the media of the developing aorta and coronary arteries decreased with increasing cell differentiation ( Figure SC) .
Discussion
In the embryonic heart, a complex process of cytodifferentiation and morphogenesis leads to the development of the myocardium, the cardiac vascular system, and the cardiac valve apparatus. In the rat, these ontogenic events continue after birth, and the histological structure of the coronary arteries undergoes important evolution in the neonatal period.2021
Three growth factors -bFGF, aFGF, and TGF-f1have been previously identified in the heart and may play an important role in the growth and differentiation of this organ.1 9 In the present study, we investigated the cellular and tissue distributions of immunoreactive bFGF and aFGF in the hearts of rat embryos and postnatal rats and compared their distributions with that of TGF-f1.
Immunoreactive bFGF and aFGF were identified in all cardiac cell phenotypes and tissues from early Immunolocalization of basic fibroblast growth factor (bFGF) and acidic fibroblast growth factor (aFGF) in vessels. Panel A: Large artery from a 14-day embryo (Masson staining); single layer ofsmooth muscle cells forms developing media. Panel B: Large artery from same embryo shown in panel A; smooth muscle cells show immunoreactivity for bFGF as intense as surrounding mesenchyma (antibody 78). Panels C and D: Dorsal aorta of 18-day embryo; at this stage, smooth muscle cells of multilayer media show stainingfor bFGF (antibody 773) in panel C and aFGF (antibody 119) in panel D that is clearly less intense than that of surrounding mesenchyma. Panel E: Intramural coronary artery of 1-day rat; immunoreactivity for aFGF (antibody 119) is similarlypositive in smooth muscle cells ofarterial media and in surrounding myocytes. Panel F: Intramural coronary artery of 5-week rat; at this stage, staining for aFGF (monoclonal antibody) is less intense in smooth muscle cells of arterial media than in surrounding myocytes. Bars in panels A-F represent 50 pm. FIGURE 
Immunolocalization of trans-
forming growth factor-/1 (TGF-f31) in rat heart at different stages of development. Panel A: Heart of 11-day embryo; immunoreactive TGF-31 (LC antibody) is present in myocytes, endothelial cells, and extracellular matrix. Pattem of immunostaining is similar to that of bFGF ( Figure 3A ) and aFGF ( Figure 3B ). Panel B: Heart of 17-day embryo; TGF-Pi (anti-pre antibody) is present in myocytes and cushions (arrow). Panel C:
Intramural coronary artery of S-week rag; at this stage, stainingfor TGF-813 (LC antibody) is less intense in smooth muscle cells of arterial media than in surrounding myocytes. Pattern ofimmunostaining is similar to that of aFGF shown in Figure 4F . Bars in panels A-C represent 50 ,gm. stages of differentiation. In most of these cell types, immunoreactivity for bFGF and aFGF remained positive throughout subsequent cytodifferentiation and organogenesis. Immunoreactive bFGF and aFGF were localized in the cytoplasm and the extracellular matrix. This widespread distribution of bFGF and aFGF in the embryonic heart suggests that these two growth factors play an important role in cardiac development and morphogenesis. In addition, each of the several antibodies used in the present study identified similar, virtually superimposable cellular and tissue distributions of immunoreactive bFGF and aFGF, a finding that suggests some form of functional interaction between these two peptides in the developing heart. We also identified progressive changes in the distribution of immunoreactive bFGF and aFGF that appeared to be associated with the process of cellular and tissue differentiation and were very similar for each of the two growth factors. These changes in the time course of expression of bFGF and aFGF suggest changes in the regulatory effects of these growth factors during cardiac morphogenesis.
Myocardium
At early stages of embryonic development, the myocytes are the only cell phenotype present in the myocardium, and the myocardium is composed of only one or two cell layers.22 At this early stage, immunoreactivity for bFGF and aFGF was already intensely positive in the myocytes and remained positive throughout subsequent embryonic development. The presence of immunoreactive bFGF and aFGF in the cardiac myocytes from early stages of development is consistent with the hypothesis that these peptides may play an important role in cardiac myocyte proliferation and differentiation in the embryo, when a rapid increase in cell number is the prevailing mechanism of heart growth. 23, 24 At birth, cardiac myocytes are already highly differentiated, and they lose their capacity to divide within a few days of birth.23,24 Subsequent heart growth is the consequence of an increase in size rather than of an increase in number of myocytes. However, immunoreactive bFGF and aFGF were identified in the myocytes throughout the postnatal period examined. The continuing presence of bFGF and aFGF in mature cardiac muscle cells, which are differentiated and incapable of cell division, implies that these peptides have functions after birth other than stimulation of cell differentiation and proliferation. This hypothesis is also supported by previous observations showing differences in fibroblast growth factors between mature and embryonic tissues. For example, the number of fibroblast growth factor receptors has been shown to decrease with increasing tissue differentiation in embryos25 and to be lower in adult tissues than in embryonic tissues. 26 In addition, messenger RNA expression for bFGF is weak or undetectable in many adult tissues.27 At this early stage of investigation, the functions of bFGF and aFGF in adult cardiac myocytes remain unknown. It is tempting to speculate that bFGF and aFGF may be stored in the adult myocytes and used in conditions associated with myocyte growth, such as ventricular hypertrophy; data supporting this hypothesis, however, are not available at present. It is also possible that the effects of these peptides in adult myocytes are not confined to cell growth but involve other, undefined cell functions.
Vessels
In the early functional embryonic heart, the myocardium does not contain capillaries, and the stillthin heart wall is supplied with oxygen by direct diffusion from the ventricular lumen.20 At later stages, when the thickness of the myocardium increases, myocardial perfusion requires capillarization of the heart wall. Development of the capillary bed of the heart begins in the outer layers of the myocardium and results from differentiation of mesenchymal cells called angioblasts, which form the single layer of endothelial cells constituting the capillary wall. 28, 29 In the embryonic rat heart, capillaries begin to form during the last quarter of the gestation period.21 At this stage, immunostaining for bFGF and aFGF was positive but not uniform in the capillary endothelium, with some cells showing staining of the same intensity as the surrounding myocytes and others showing only faint or no staining. In mammals, capillary endothelial cells continue to proliferate and divide throughout life. Thus, the differences in immunoreactivity that we identified in endothelial cells might be related in part to differences in the cell cycle of individual cells.
In mammalian and avian embryos, development of the smooth muscle cells of the arterial media proceeds at different rates in large and small arteries.20,21 For example, in the rat, the media of the aorta develops during embryonic life, whereas the media of the intramural coronary arteries develops during the neonatal period.20, 21 We identified progressive changes in immunoreactivity for bFGF and aFGF in the smooth muscle cells of the media of the arteries. These changes were very similar for the two peptides and appeared to be associated with the process of smooth muscle cell differentiation in both large and small arteries. At early stages of development of the rat embryo, a single layer of smooth muscle cells can be identified between endothelium and adventitia in the dorsal aorta and other large arteries. This single layer of smooth muscle cells showed intense staining for bFGF and aFGF. At later stages of embryonic development, when the media of the large arteries consists of several layers of more differentiated smooth muscle cells, staining in the media became nonuniform and faint, and it remained unchanged in the postnatal period.
In the smooth muscle cells of the media of the intramural coronary arteries, immunoreactivity for bFGF and aFGF showed progressive changes that paralleled those in the large arteries but occurred during the neonatal period. Immediately after birth, immunostaining was positive and intense in the monolayer media of the intramural coronary arteries. After the first week of life, staining became faint in the now-multilayer media of some of these arteries (usually the larger arteries); by 4 weeks after birth, it was faint or negative in most of the intramural coronary arteries.
The inverse relation that we identified between degree of smooth muscle cell differentiation and presence of immunoreactive bFGF and aFGF suggests that the role of these growth factors may change during the time course of angiogenesis and that bFGF and aFGF are necessary to the developing smooth muscle cells of the arterial media but have a less important role in regulating the functions of mature smooth muscle cells in physiological conditions. We speculate that these peptides could be expressed again and resume a role in pathological conditions. For example, they might play a part in the intense smooth muscle cell proliferation that has been identified in certain pathological conditions, such as the restenosis after percutaneous transluminal coronary angioplasty in humans. 30 
Valve Apparatus
In rat embryos, at the beginning of the second half of the gestation period, mesenchymal cells that lack the morphological markers of cardiac muscle cells (myofibrils and glycogen pools) form opposing cushions at the base of the heart.31 These cells derive from endocardial cells that change their phenotype to that of mesenchymal cells and migrate into the cardiac jelly.32 In the rat embryos, the mesenchymal cells of the cushions showed positive immunostaining for bFGF and aFGF throughout development. However, at later stages of development, the intensity of immunostaining for bFGF and aFGF in the cushions became nonuniform, with some areas showing intense staining and others showing only faint staining. During cardiac morphogenesis, the mesenchymal cells of the cushions undergo a complex process of migration and differentiation that leads to the formation of the cardiac valves, the aorta, the main pulmonary artery, and portions of the atrial septum and the ventricular septum. It is possible that the changes we identified in the distribution of immunoreactive bFGF and aFGF in the mesenchyma of the cushions are related to the different destinies of individual mesenchymal cells in the complex morphogenetic evolution of the cushions. The widespread distribution of these two growth factors in the cardiac cushions also suggests the possibility that alterations in their cellular localization and availability could lead to congenital cardiac malformations.
The completely developed cardiac valves consist mainly of fibrous connective tissue covered by an endothelial layer.33 Present within this fibrous connective tissue are elastic fibers, proteoglycans, and connective tissue cells (including fibroblasts and smooth muscle cells). In the later stages of embryogenesis, when mor-phogenesis of the cardiac valves is completed, immunostaining for bFGF and aFGF was positive in the endocardial and connective tissue layers of the valves and remained positive and intense throughout the postnatal stages examined. The heart valves are exposed to high mechanical forces and undergo continuous repair and cellular renewal to maintain normal valvular morphology and function. The continuing presence of bFGF and aFGF in the valve apparatus suggests that these growth factors may participate in the process of valvular tissue maintenance.
Comparison of Localization of TGF-f81 With That of bFGF and aFGF
Previous studies have identified TGF-p1 in the hearts of embryonic and neonatal mice,8,9 and recent observations have shown that this peptide mediates, in part, the transformation of endothelial cells into mesenchymal cells in the heart cushions. 34 In the present investigation, the distribution of immunoreactive TGF-f81 in the developing rat heart was very similar to that of bFGF and aFGF at each stage examined. TGF-,31 is known to inhibit proliferation and differentiation of many cell types; recently, it has been shown to inhibit in vitro the mitogenic effects of bFGF on endothelial cells and cardiac neonatal myocytes. 35 Because tissue differentiation and development probably involve the complex interaction of both stimulatory and inhibitory factors, the similarities we identified in the distributions of immunoreactive TGF-f1, bFGF, and aFGF may reflect integrated regulatory functions of these three peptides during heart development.
Conclusions
The results of the present investigation demonstrate that bFGF and aFGF are widely distributed in rat heart tissues from early stages of embryonic development throughout the postnatal period. This finding suggests that these growth factors play an important role in the complex process of cytodifferentiation and morphogenesis that leads to the development of the myocardium, the vessels, and the cardiac valve apparatus. In addition, the similarities in the cellular and tissue distributions of bFGF and aFGF that we found in the heart may reflect some form of functional interaction between these peptides. Finally, the progressive changes we identified in the distributions of bFGF and aFGF in the mesenchymal cells of the cardiac cushions and the smooth muscle cells of the arterial media suggest that the role of these growth factors changes during development of the cardiovascular system.
